Safety Shot, Inc.

As of August 14, 2025, Safety Shot, Inc. is deemed overvalued and not a viable investment due to negative financial metrics, including a Price to Book Value of -20.94, while its peers show more favorable valuations.

As of August 16, 2021, Safety Shot, Inc. is considered overvalued and risky due to severe financial distress indicated by a Price to Book Value of -20.94, an EV to EBITDA of -0.80, and a ROCE of -782.57%, significantly underperforming compared to peers like Olaplex Holdings and Natural Health Trends, with a year-to-date return of -54.56% against the S&P 500's 2.44% gain.

As of May 14, 2025, Safety Shot, Inc. is in a bearish trend with weak strength, indicated by daily moving averages, monthly MACD, and KST showing bearish conditions, along with mildly bearish Bollinger Bands and confirmation from Dow Theory.

As of March 2022, the management team of Safety Shot, Inc. includes Dr. Glynn Wilson (Chairman and Head of R&D), Mr. Brian John (CEO), Mr. Richard Miller (COO), and several independent directors: Dr. Hector Alila, Mr. Timothy Glynn, Mr. Christopher Melton, and Mr. Byron Young. They oversee the company's strategic direction and operations.

Safety Shot, Inc. is a wellness company focused on developing hemp-derived cannabidiol (CBD) consumer products, with a market cap of USD 20.90 million. As of March 2025, it reported net sales of USD 0 million and a net profit loss of USD 5 million.

As of Jun 18, Safety Shot, Inc. has a market capitalization of 20.90 million, with net sales of 1.04 million and a net profit of -38.06 million over the last four quarters. The company's shareholder's funds were -2.17 million, and total assets amounted to 7.34 million as of Dec 24.